Government and private insurers are placing unprecedented pressures on Life Sciences companies to demonstrate value for the products they develop, according to The 2009 Ernst & Young business risk report, Life sciences. Insurers, governments and individuals are likely to increase demands to demonstrate value in the years ahead, as they confront mounting healthcare costs, a shrinking tax base, aging populations, and a mandate to provide care for a larger pool of citizens.
The top 5 risks facing Life Sciences companies:
1. Demonstrating value and pricing pressures
2. Capital access/capital allocation
3. Boosting R&D productivity
4. Revolutionizing business models
5. Ensuring safe products
LINK
Tuesday, May 12, 2009
E&Y: Top 5 Risks to Life Sciences Companies
